Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.
about
Who Benefits from Chronic Opioid Therapy? Rethinking the Question of Opioid Misuse RiskOpioid-induced constipation: advances and clinical guidanceIntractable restless legs syndrome: role of prolonged-release oxycodone-naloxoneConsensus Recommendations on Initiating Prescription Therapies for Opioid-Induced ConstipationEmerging therapies for patients with symptoms of opioid-induced bowel dysfunctionChronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunitiesDevelopment of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioidsOpioid-induced constipation: pathophysiology, clinical consequences, and management.Tolerability of Opioid Analgesia for Chronic Pain: A Network Meta-AnalysisEfficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrenceLong-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trialsQuality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxoneLong-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.Long-term chronic opioid therapy discontinuation rates from the TROUP studyA randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study.Oxycodone and Naloxone Combination: A 12-Week Follow-up in 20 Patients Shows Effective Analgesia Without Opioid-Induced Bowel Dysfunction.Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study.Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.Opioid-induced constipation: challenges and therapeutic opportunities.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatment options for chronic constipation: mechanisms, efficacy and safety.Combined oral prolonged-release oxycodone and naloxone in chronic pain management.Oxycodone combined with opioid receptor antagonists: efficacy and safety.The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilitiesOxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment.Lubiprostone for Opioid-Induced Constipation Does Not Interfere with Opioid Analgesia in Patients with Chronic Noncancer Pain.Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson's disease patients with chronic pain.Prolonged-release oxycodone/naloxone in opioid-naïve patients - subgroup analysis of a prospective observational study.Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.High doses of oxycodone-naloxone combination may provide poor analgesia.Opioid/naloxone prolonged release combinations for opioid induced constipationThe place of oxycodone/naloxone in chronic pain management.Opioid-induced bowel dysfunction.Validated in vitro/in vivo correlation of prolonged-release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times.Oxycodone/Naloxone Prolonged Release: A Review in Severe Chronic Pain.
P2860
Q26740264-DD7A295C-73E8-429D-A23C-21CB7E33FC0FQ26765571-77C9BADE-822C-4140-8C79-0B9D2F8B948AQ26766416-A0791113-FB2A-4835-AE52-6F2BBA1526B2Q26830397-0347B40E-20E4-4594-9F70-B14CCC2C68DAQ27010907-6CD82A78-BECD-4F65-952C-BA015AE36689Q28083547-081A876D-FACB-4BE3-98E0-12D10D9BF275Q30989361-4D632125-1969-4F07-898A-4A79665EA8FBQ33635040-B20F9DE9-69D8-4503-9D30-22B10C1795FCQ33700472-F2D82A96-2A3B-4CB5-8731-A3DBD927F20BQ33709851-7B991C2E-E416-44DA-A0FD-0204343A1F8FQ33938740-A45E73C7-B36C-449A-A2A0-DFC3F543F5E7Q34693351-642567CB-D56E-4F32-A7B6-2B0D12A0138DQ34798408-C7F2F2A1-9C4D-41B8-8AAE-39E504484E3BQ35028902-A8F15772-0F63-4840-9A0C-015DD2602A34Q35606850-7D2779B8-9015-4476-A1A9-1E907F4FA631Q35664979-C75E93CA-9894-42E1-86D0-868B8DA8D1D8Q36833660-92937789-B5FA-4635-9AE8-DE01B8CFEDCFQ37018633-E1F101C4-F631-4031-B654-9421BD6F21CCQ37031540-C98500C5-5B9F-4B53-A972-E824AC0B28B6Q37171216-5F7D3AB7-BE68-472F-8947-A1E641189ECAQ37200907-1C6EB37C-BFF3-47DB-B0B2-35778909B8F1Q37846099-ADFCF401-3F73-4956-8775-305A9A2ED27BQ37954521-9AABC782-1F9A-4CC2-85D7-0C8B6E05C340Q37960501-849E01C2-DA42-4894-85F1-E22EDBE0B06BQ38065187-F980FC97-8A7C-468E-B3F7-0A7C05988E25Q38093671-A9EB6B6F-3C31-4ACD-BE22-DDE63C1D06ADQ38116004-D171927F-5943-4D6D-A1A4-FA35C9D502ACQ38181019-7105205D-F47B-4826-ACF7-D783352EBA77Q38772298-4D6F3976-D0AD-4256-A19E-F1823987F673Q39151428-61791FD8-B8B1-41EE-A2F4-1871DE56B7BDQ39175158-97C807E5-02A0-4748-824D-AFC6E0663EF6Q39187047-81351D32-654E-4E7A-87AC-8DE3685475AEQ39195336-6D666617-F8B9-4E39-BCF3-64A10C1A575FQ39235593-0654DE87-9836-4EDF-A3C8-6B14191AD22FQ39264580-F6C4D215-1C9D-4DE0-BC85-346EC06C5B0EQ42010768-DFF943A1-A296-4A7C-A4C8-5A2BE4A6E562Q42161578-1675AF68-DD3A-44F9-9DA2-B0D98087E417Q42323281-9DA492FE-9E00-4937-B5BE-FE924E6E898AQ42670437-751A76C2-E5E6-4102-AF40-B825CCE040A0Q43075620-2AB29423-A35B-432D-9ECC-3014FA983017
P2860
Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Long-term efficacy and safety ...... nt of non-cancer chronic pain.
@ast
Long-term efficacy and safety ...... nt of non-cancer chronic pain.
@en
Long-term efficacy and safety ...... nt of non-cancer chronic pain.
@nl
type
label
Long-term efficacy and safety ...... nt of non-cancer chronic pain.
@ast
Long-term efficacy and safety ...... nt of non-cancer chronic pain.
@en
Long-term efficacy and safety ...... nt of non-cancer chronic pain.
@nl
prefLabel
Long-term efficacy and safety ...... nt of non-cancer chronic pain.
@ast
Long-term efficacy and safety ...... nt of non-cancer chronic pain.
@en
Long-term efficacy and safety ...... nt of non-cancer chronic pain.
@nl
P2093
P2860
P1476
Long-term efficacy and safety ...... nt of non-cancer chronic pain.
@en
P2093
A Sandner-Kiesling
P Leyendecker
P2860
P304
P356
10.1111/J.1742-1241.2010.02360.X
P50
P577
2010-03-29T00:00:00Z